SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards as investors react to increased AI spending plans and a large one-time tax charge, overshadowing otherwise positive earnings results. Despite a record-breaking bond offering, the community is debating whether this dip represents a buying opportunity or reflects deeper concerns about Meta's capital expenditures. Some traders are closely watching key support levels and potential for a rebound, while others express skepticism about the long-term profitability of Meta's AI investments.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as investors discuss potential catalysts from upcoming earnings, including a possible S&P 500 inclusion and buybacks. Community sentiment is mixed, with some expressing concerns about the company's correlation to Bitcoin and the impact of potential dilutions. Some traders are anticipating volatility post-earnings, while others believe the stock is oversold and due for a bounce.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors brace for its earnings report, with the central focus being ad revenue and AI partnerships. Community members are weighing the potential for a significant post-earnings move, drawing comparisons to META's recent performance, while also highlighting high short interest as a possible catalyst for a squeeze. Some traders express caution about the stock's valuation and potential for a selloff if earnings disappoint.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards, with the community expressing concerns about recent price action and continued stock dilution; some are questioning the company's overall strategy and the credibility of bullish forecasts, while others remain optimistic about the long-term potential of Ethereum and BMNR's accumulation strategy.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors anticipate its upcoming earnings report, focusing on the performance of AWS and its AI initiatives. Community sentiment appears mixed, with some expressing concerns about AWS growth and profitability, while others are optimistic about a potential breakout. The layoffs, framed as a strategic move towards AI, are also being heavily discussed.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as investors anticipate upcoming earnings, with some expecting a significant move in either direction. Community members are actively discussing potential outcomes and strategizing based on technical analysis and unusual options activity. The broader tech sector and potential AI developments remain a key focus for Apple's future growth.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors react to strong earnings, highlighting growth in cloud services and advertising revenue, with particular attention to the company's AI initiatives. The community is debating whether the stock's recent surge has priced in future growth, while analysts are raising price targets and citing Google's leadership in AI. Some traders are expressing concern about the run-up into earnings, while others are locking in profits or betting on continued upside.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid speculation of a potential acquisition, fueled by a recent report suggesting the company is in talks for a significant deal. The community is actively discussing potential buyout prices and speculating on which pharmaceutical company could be the acquirer, with some pointing to the company's oncology pipeline as a key attraction. Despite the positive price movement, some investors remain cautious, citing upcoming earnings and potential legal liabilities.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards as investors react to concerns about slowing revenue growth and declining traffic, particularly among younger, lower-income consumers. The community is discussing the impact of these trends on the company's future, with some suggesting the need for strategic changes and others viewing the dip as a buying opportunity. There is also debate around the value proposition offered by Chipotle compared to competitors amidst rising costs.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid buyout speculation and renewed interest from SpaceX, driving community excitement about a potential bidding war. The community is buzzing about possible high buyout figures and the implications for existing partnerships, including the Apple deal. Discussions also involve Globalstar's spectrum value and potential combinations with other industry players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit

Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit As noted earlier, investors face a monumentally important and extremely busy week ahead that includes rates...

Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting 2025, hosted by the...

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior day's close.

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...

Retail buzz spiked around Gilead Sciences Inc. after the biotech firm&nbsp;on Sunday revealed new data showing that its cancer drug Trodelvy helped patients with one of the most aggressive forms of breast cancer live significantly longer before their disease worsened.The results come from Gilead’s Phase 3 ASCENT-03 trial, which found that combining Trodelvy with chemotherapy cut the risk of disease progression or death by 38% compared with chemotherapy alone.&nbsp;Trodelvy Helps Patients Live Longer Without ProgressionThe trial included patients with metastatic triple-negative breast cancer (TNBC) who are ineligible for immunotherapy. Patients treated with Trodelvy had a median progression-free survival (PFS) of just under 10 months, while those on standard chemotherapy had a PFS of about 7 months.The duration of responses was also improved, with 12 months on Trodelvy versus just over&nbsp;seven months on chemo. Javier Cortes, who led the study at the International Breast Cancer Center in Spain, said it could "represent the first major treatment advance for this patient population in the 20 years since TNBC was defined."Manageable Side Effects&nbsp;Gilead said Trodelvy’s safety profile was consistent with earlier studies, and most side effects were manageable. The most common were neutropenia (low white blood cell counts) and diarrhea, but fewer patients stopped treatment compared to those on chemotherapy.Dietmar Berger, Gilead’s Chief Medical Officer, said Trodelvy could become the first antibody-drug conjugate (ADC) used as a standard first-line treatment for TNBC, offering a “much-needed” alternative to chemotherapy.”The company is already in talks with the U.S. Food and Drug Administration (FDA) and global regulators about expanding the drug’s approval for earlier-stage use.A Bigger Role Ahead For TrodelvyThese results build on earlier findings from another Gilead study, ASCENT-04/KEYNOTE-D19, where Trodelvy, when paired with Keytruda (pembrolizumab), showed strong benefits for PD-L1-positive TNBC patients.Trodelvy, which targets the Trop-2 protein, is already approved in over 50 countries to treat later-line TNBC and HR+/HER2– breast cancers. Gilead is also testing it in lung and gynecologic cancers, signaling its ambition to make the drug a cornerstone of its cancer portfolio.Stocktwits Users See Gilead Riding Defensive-Sector StrengthOn Stocktwits, retail sentiment for Gilead was ‘extremely bullish’ amid ‘high’ message volume.One user described the stock as one of their top holdings and noted steady inflows into defensive names like healthcare, with Gilead seen as benefiting from renewed growth momentum.&nbsp;<stembedurl>https://stocktwits.com/ArcherSLV/message/632850999</stembedurl>Another user pointed to a technical breakout in the stock.<stembedurl>https://stocktwits.com/howardlindzon/message/632907201</stembedurl><a href="https://stocktwits.com/symbol/GILD">Gilead’s stock</a> has risen 36% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial

The data positions Trodelvy as a potential new standard of care for patients with metastatic triple-negative breast cancer who aren’t eligible for immunotherapy.

Equity

🚨 LIVE Earnings on Polymarket. 
Trading earnings just got much simpler: Will your favorite stock beat earnings – Yes or No?

Polymarket

Gilead Sciences, Inc.

GILD  Earnings Call

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GILD News

GILDGilead Sciences, Inc.